

## BRIEF REVIEW

## Severe COVID-19

Arpan Harshadkumar Chawala<sup>1</sup>, MD; Shivam Gulati<sup>1</sup>, MD; Bettina Sinanova<sup>2</sup>; Jose Bordon<sup>1,2\*</sup>, MD PhD

<sup>1</sup>Division of Infectious Diseases, Center of Excellence for Research in Infectious Diseases (CERID), University of Louisville School of Medicine, Louisville, KY, USA,

<sup>2</sup>Washington Health Institute, Washington, D.C., USA

\*jbordon@dc-whi.org

**Recommended Citation:** Chawala AH, Gulati S, Sinanova B, Bordon J. Severe COVID-19. *Univ Louisville J Respir Infect* 2020; 4(1):Article 55. doi: 10.18297/jri/vol4/iss1/55.

## Abstract

**Introduction:** There is substantial variation in the clinical characteristics and outcomes of severe coronavirus disease (COVID-19), making it difficult to do an optimal assessment of this condition. We reviewed the current English literature to identify the findings concerning the baseline characteristics and health outcomes of patients with severe COVID-19, primarily those with acute respiratory distress syndrome (ARDS).

**Methods:** We examined only studies that assessed patients with confirmed COVID-19 by reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with at least one of the following severity criteria: treated in the intensive care unit (ICU), ARDS, and/or invasive mechanical ventilation (IMV) treatment. We assessed the quality of the studies according to the National Heart, Lung and Blood Institute study quality assessment tools.

**Results:** Seven of 39 studies fulfilled the inclusion criteria. These seven studies included a total 1,863 patients; the me-

dian age was 63.5 years (range 49–70). A total 370 (19.8%) were females. Four studies were from the USA, two from China and one from Italy. Comorbidities were reported in six studies. Fever was reported in five studies and was present in 159 out of 272 patients. Cough and shortness of breath (SOB) were reported in four studies, present in 111 out of 142 and 100 out of 142 patients, respectively. The median total lymphocytes was reported in five studies with a range of 400–889/ul. IMV ranged from 15% to 100%, and mortality ranged from 14.6% to 88%. In a subgroup analysis by country, patients from the US showed more comorbidities and higher percentages of IMV and mortality. The mean assessment quality score of the seven studies was 5 out of a maximum 9.

**Conclusions:** Severe COVID-19 was predominantly seen in male patients who were 60 years or older and was associated with comorbidities. Most of the patients were admitted to the ICU and needed IMV support due to ARDS, and the overall mortality rate had a range of 14.6–88%.

## Introduction

The new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of the coronavirus disease-19 (COVID-19) and it was originally reported in Wuhan, China in December 2019. Today this unprecedented COVID-19 pandemic spread to the whole globe resulting in about 7,500,000 infected people and the loss of about 430,000 humans lives.[1] In relation to the severity of illness, COVID-19 has a spectrum of clinical presentations. Severe COVID-19 has been reported in about 14 % of patients with a fatality rate of 49%.[2] In the time of severe COVID-19 leading to an unexpectedly high number of deaths, it is important to examine history to reassure our best approaches to a new problem. Though severe COVID-19 is new for us, similar epidemics happened over time. In this

regard, the historical quote the “Captain of the Men of Death” which was originally coined by John Bunyan for tuberculosis is very timely and wise to relate to severe COVID-19.[3] It is tempting to conceive that COVID-19 is the current Captain of Death.

It is important to highlight the exponential health care burden, morbidity, and mortality of severe COVID-19. The American Hospital Association estimates a total four-month financial impact of \$202.6 billion in losses for America’s hospitals and health systems, or an average of \$50.7 billion per month.[4] The UN’s Trade and Development Agency says the slowdown in the global economy caused by the coronavirus outbreak is likely to cost at least \$1 trillion.[5]

There are substantial variabilities of the clinical characteristics and outcomes of severe COVID-19, which

creates difficulty in doing an optimal assessment of this condition. Though severe COVID-19 has been reported to present as septic shock, acute cardiac complication, stroke and involving many other organs; there is increasing evidence that the lung involvement resulting in ARDS is the most common and fatal complication.[6] The objective of the study is to review the current English literature to quantify the findings of clinical presentation and health outcomes of patients with severe COVID-19 primarily with acute respiratory distress syndrome (ARDS).

## Methods

### *Database search strategies*

We did a search in PubMed and Google Scholar using the queries "COVID-19", "Severe COVID-19", "Clinical Characteristics" and "Clinical Outcomes".

### *Inclusion criteria*

Studies that assessed patients with proven COVID-19 by RT-PCR for SARS-CoV-2. These studies examined and provided data of patients with severe COVID-19, patients treated in the ICUs, patients with the diagnosis of ARDS and patients who were receiving treatment with invasive mechanical ventilation.

### *Exclusion criteria*

Studies that did not include cases according to the inclusion criteria. Studies that claimed including cases according to our inclusion criteria, but they did not provide baseline clinical characteristics and outcomes.

### *Quality assessment*

We assessed the quality of the studies according to the National Heart, Lung and Blood Institute, Study Quality Assessment Tools.[7]

## Results

### *Selected publications*

Our search in the databases PubMed and Google Scholar revealed 39 publications. A total 32 publications were excluded according to the exclusion criteria and we selected eight publications for our review. Subsequently, a publication that reported assessing severe COVID-19 was eliminated because the reported findings were not consistent with severe COVID-19. This study reported A-a gradient for the non-severe and severe COVID-19 of 3.9 vs. 4.0 respectively. These reported severe cases showed a rate of ARDS of 15.6%, intensive care unit (ICU) admission of 19.1% and a mortality of 8.1%. This clearly indicates that most of these

cases were not severe COVID-19.[8] Therefore, there were seven publications for our review.[2, 9-14]

### *Total severe COVID-19 cases included by gender and age*

Our study included a total 1,863 patients, the median age was 63.5 years and range was 49–70 years. A total 370 (19.8%) were females. Four studies were from the USA, two from China and one from Italy.[2, 9-14]

### *Reported comorbidities*

The comorbidities reported in six studies were as follows: diabetes mellitus 254 (13.6%), arterial hypertension 604/1818 (33.2%), chronic obstructive pulmonary disease (COPD) 58/1779 (3.3%), chronic kidney disease (CKD) 51/1636 (3.1%).

### *Clinical symptoms*

Fever was reported in five studies and it was reported to be present in 159 out of 272 patients included in the five studies. Cough and shortness of breath (SOB) were reported in four studies. In these four studies, cough was present in 111 out of 142 patients and SOB in 100 out of 142. None of the study reported vomiting and diarrhea.

### *Laboratory studies*

The median of total lymphocytes was reported in five studies with a range of 400 – 889/ul. The arterial partial pressure of oxygen/fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) ratio was reported in three studies with a range of 69-492 (median 160).

### *Imaging studies*

Imaging studies were reported only in four studies. Bilateral lung infiltrates in chest X-ray were reported in 161 out of 188 (85.6%) patients and ground-glass opacities (GGO) on computerized tomography (CT) in 15 out of 45 patients (33.3%).

### *Outcomes*

Baseline outcomes are depicted in **Table 1**.

### *Comparison of baseline clinical characteristics and outcomes in patients from USA and China*

To find out whether the type of medical practice and patient population by country could have influenced the clinical characteristics and outcomes, we compared the cases of severe COVID-19 by country. In this comparison, patients reported in the US showed more comorbidities more often, higher percent of IMV and mortality than those from China (**Table 2a and Table 2b**).

**Table 1.** Baseline characteristics and outcomes of patients with severe COVID-19.

Study	Clinical characteristics	Outcomes
Grasselli <i>et al.</i> [10] Journal: <i>JAMA</i> Number of patients: 1,591 Severity criteria: ICU admission Country: Italy	Median age 63 years Female 18% DM 17%, HTN 49%, COPD 4%, CKD 3% PaO <sub>2</sub> /FiO <sub>2</sub> median 160	Mortality 26% IMV 88%
Arentz <i>et al.</i> [11] Journal: <i>JAMA</i> Number of patients: 21 Severity criteria: ICU admission Country: USA	Median age 70 years Female 48% DM 33.3%, COPD 33.3%, CHF 42.9%, CKD 47.6% Fever 52%, SOB 76% Total lymphocyte 889/ul PaO <sub>2</sub> /FiO <sub>2</sub> ratio 169 CXR lung infiltrates 52%, b/l GGO 48%	Mortality 52.4% IMV 71%
Bhatraju <i>et al.</i> [12] Journal: <i>NEJM</i> Number of patients: 24 Severity criteria: ICU admission Country: USA	Mean age 64±18 (23–97) years Female 38% DM 58%, CKD 21%, COPD 4% Fever 50%, SOB 88% Total lymphocytes 720/ul CXR lung infiltrates 100%, CT GGO 80%	Mortality 50% IMV 75%
Huang <i>et al.</i> [13] Journal: <i>Lancet</i> Number of patients: 13 Severity criteria: ICU admission Country: China	Median age 49 years Female 15% DM 8%, HTN 15%, COPD 8%, CVD 23% Fever 100%, SOB 92% Total lymphocytes 400/ul, D-dimer 2.4 mg/L CXR lung infiltrates 100%	Mortality 38% ARDS 85% IMV 15% NIMV 62% Septic shock 23% Cardiac injury 31% AKI 23%
Wu <i>et al.</i> [2] Journal: <i>JAMA IM</i> Number of patients: 84 Severity criteria: ARDS Country: China	Median age 58.5 years Female 28.6% DM 19%, HTN 27.4% Fever 92.9%, SOB 59.5%, cough 81% Total lymphocytes 670/ul CRP 83 D-dimer 1.16 mg/L	Mortality 47.6% ICU 26.6% ARDS 41.8% IMV 21.3%
Goyal <i>et al.</i> [14] Journal: <i>NEJM</i> Number of patients: 130 Severity criteria: IMV Country: USA	Median age 64.5 years Female 29.2% DM 27.7%, HTN 70 53.8%, COPD 5.4% Fever 34.6% CXR lung infiltrates 87.7%	Mortality 14.6%
Richardson <i>et al.</i> [9] Journal: <i>JAMA</i> Number of patients: 373 Severity criteria: ICU admission Country: USA	Total lymphocytes 800/ul	Mortality 88% IMV 320/373, 85.7% Mortality in IMV 282/230, 88%

**Abbreviations:** AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computerized tomography; CVD, cardiovascular disease; CXR, chest X-ray; DM, diabetes mellitus; GGO, ground-glass opacities; HTN, hypertension; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIMV, noninvasive mechanical ventilation; PaO<sub>2</sub>/FiO<sub>2</sub>, arterial partial pressure of oxygen/fraction of inspired oxygen; SOB, shortness of breath.

**Table 2.** Baseline characteristics and outcomes of patients with severe COVID-19 by country.

**a) Studies from the USA.**

Study	Clinical characteristics	Outcomes
Arentz <i>et al.</i> [11] Journal: <i>JAMA</i> Number of patients: 21 Severity criteria: ICU admission Country: USA	Median age 70 years Female 48% DM 33.3%, COPD 33.3%, CHF 42.9%, CKD 47.6% Fever 52%, SOB 76% Total lymphocyte 889/ul PaO <sub>2</sub> /FiO <sub>2</sub> ratio 169 CXR lung infiltrates 52%, b/l GGO 48%	Mortality 52.4% IMV 71%
Bhatraju <i>et al.</i> [12] Journal: <i>NEJM</i> Number of patients: 24 Severity criteria: ICU admission Country: USA	Mean age 64±18 (23–97) years Female 38% DM 58%, CKD 21%, COPD 4% Fever 50%, SOB 88% Total lymphocytes 720/ul CXR lung infiltrates 100%, CT GGO 80%	Mortality 50% IMV 75%
Goyal <i>et al.</i> [14] Journal: <i>NEJM</i> Number of patients: 130 Severity criteria: IMV Country: USA	Median age 64.5 years Female 29.2% DM 27.7%, HTN 70 53.8%, COPD 5.4% Fever 34.6% CXR lung infiltrates 87.7%	Mortality 14.6%
Richardson <i>et al.</i> [9] Journal: <i>JAMA</i> Number of patients: 373 Severity criteria: ICU admission Country: USA	Total lymphocytes 800/ul	Mortality 88% IMV 320/373, 85.7% Mortality in IMV 282/230, 88%

**b) Studies from China.**

Study	Clinical characteristics	Outcomes
Huang <i>et al.</i> [13] Journal: <i>Lancet</i> Number of patients: 13 Severity criteria: ICU admission Country: China	Median age 49 years Female 15% DM 8%, HTN 15%, COPD 8%, CVD 23% Fever 100%, SOB 92% Total lymphocytes 400/ul, D-dimer 2.4 mg/L CXR lung infiltrates 100%	Mortality 38% ARDS 85% IMV 15% NIMV 62% Septic shock 23% Cardiac injury 31% AKI 23%
Wu <i>et al.</i> [2] Journal: <i>JAMA IM</i> Number of patients: 84 Severity criteria: ARDS Country: China	Median age 58.5 years Female 28.6% DM 19%, HTN 27.4% Fever 92.9%, SOB 59.5%, cough 81% Total lymphocytes 670/ul CRP 83 D-dimer 1.16 mg/L	Mortality 47.6% ICU 26.6% ARDS 41.8% IMV 21.3%

**Abbreviations:** AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computerized tomography; CVD, cardiovascular disease; CXR, chest X-ray; DM, diabetes mellitus; GGO, ground-glass opacities; HTN, hypertension; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIMV, noninvasive mechanical ventilation; PaO<sub>2</sub>/FiO<sub>2</sub>, arterial partial pressure of oxygen/fraction of inspired oxygen; SOB, shortness of breath.

**Table 3.** Quality assessment of studies of severe COVID-19.

	Grasselli, <i>et al.</i> [10] <i>JAMA</i>	Arentz <i>et al.</i> [11] <i>JAMA</i>	Bhatraju <i>et al.</i> [12] <i>NEJM</i>	Huang <i>et al.</i> [13] <i>Lancet</i>	Wu <i>et al.</i> [2] <i>JAMA IM</i>	Goyal <i>et al.</i> [14] <i>NEJM</i>	Richardson <i>et al.</i> [9] <i>JAMA</i>
1. Was the study question or objective clearly stated?	1	1	1	1	1	1	1
2. Was the study population clearly and fully described, including a case definition?	1	1	1	1	1	1	1
3. Were the cases consecutive?	CD	CD	CD	CD	CD	CD	CD
4. Were the subjects comparable?	NR	NR	NR	NR	NR	NR	NR
5. Was the intervention clearly described?	NA	NA	NA	I	NA	NA	NA
6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?	1	1	1	1	1	0	1
7. Was the length of follow-up adequate?	1	0	1	0	1	1	1
8. Were the statistical methods well-described?	1	0	1	1	0	0	1
9. Were the results well-described?	1	1	1	1	1	0	1
Score*: /9	6	4	6	5	5	3	6

**Abbreviations:** CD, cannot determine; NA, not applicable; NR, not reported.

\* Yes=1, No=0.

### Assessment of data quality

The mean assessment of data quality score for the seven studies was 5 out of a maximum 9 (Table 3).

## Discussion

Our study examined seven studies addressing severe COVID-19 with an average quality score of 5 out of 8 points. These seven studies showed a substantial variability of the clinical characteristics and outcomes of patients with severe COVID-19. Severe COVID 19 was seen predominantly in males; six of the studies showed a range of 15% - 48% of females and an average of 29.5% female.[2,10-14] It means; less than 1 out of 5 patients with severe COVID-19 will be a woman. At the best interpretation of 4 out of 6 studies that provided the patients ages, the patients median age was 64 years and older.[10-12,14] Six of the studies revealed multiple comorbidities.[2,10-14] Diabetes mellitus, arterial hypertension and COPD were the most reported comorbidities.

The angiotensin converting enzyme (ACE)-2 has been established to play an essential role in preventing the development of the toxic inflammatory response in COVID-19.[15] Furthermore, ACE-2 was reported to decrease with aging and to have a lower expression in

males.[16] The latter is related to the fact that the ACE-2 genes map to the X chromosome.[17] Similarly, ACE-2 is expressed less in patients with comorbidities.[15] In line with these specific distributions of the expression of the ACE-2, elderly male patients with comorbidities are expected to be the main patients with severe COVID-19 as reported by the studies in our review.

An important finding of our review is that fever was not very common among patients with severe COVID-19. Fever was common in studies reported in China and these studies have a lower mortality.[2,13] This observation is in line with the statement that fever is a marker of optimal host response to an injury. Interestingly, some studies showed that fever was present in only about 50% of patients and the same studies revealed a mortality of about 50%.[2,13] It could be speculated that patients without fever were severely ill and had a poor host response resulting in death. Lymphopenia is a common laboratory marker of severe COVID-19 and it is being considered a major factor in the pathogenesis and mechanisms of the severity of COVID-19.[18] Severe COVID-19 has been associated with a cytokine release storm largely related to the ACE-2. The ACE-2 is found in many cells of different organs. ACE converts angiotensin-I into angiotensin-II, which through the angiotensin type-1 receptor (AT-1R), triggers vasoconstriction, inflammation, and thrombosis.[15] On the other hand, ACE-2 converts angiotensin



II into angiotensin 1-7, which binds to angiotensin type 2 receptor (AT-2R) triggering vasodilation, less fibrosis and less thrombosis. Thus, ACE-2 is a master regulator of the renin-angiotensin system (RAS) by converting angiotensin I and angiotensin II to 1-9 and 1-7 respectively. Because ACE-2 is the receptor of SARS-CoV-2, upon the virus binds to ACE-2, the counter regulation activity of ACE-2 over renin-angiotensin system (RAS) is lost.

Our study has some weaknesses and strengths. Some of the weaknesses are related to the few numbers of studies, the quality of the studies, lack of standardization of baseline characteristics, and outcomes. All these factors resulted in an important variability of

the characteristics and outcomes of patients with severe COVID-19. Many of the weaknesses are acceptable in view of the urgent need to report data of severe COVID-19. The strength of our review study is that according to our knowledge this is the first review study on severe COVID-19.

In conclusion, severe COVID-19 was predominantly seen in male patients aged 60 years and older associated mostly with diabetes mellitus, arterial hypertension, and COPD. Fever seems to be present in a half of the patients and more often SOB. Most of the patients were admitted at the ICU, needed IMV support due to ARDS and had a mortality range of 14.6–88%.

**Received:** June 12, 2020

**Accepted:** June 26, 2020

**Published:** July 27, 2020

**Copyright:** © 2022 The author(s). This original article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. For more information, please contact thinkir@louisville.edu. This article is

distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding Source:** The author(s) received no specific funding for this work.

**Conflict of Interest:** All authors declared no conflict of interest in relation to the main objective of this work.

## References

1. Johns Hopkins University Center for Systems Science and Engineering. COVID-19 dashboard. Available at: <https://coronavirus.jhu.edu/map.html>. Accessed 26 June 2020.
2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* **2020**; 180(7):934-43. doi: 10.1001/jamainternmed.2020.0994. PMID: 32167524.
3. Osler W. The principles and practice of medicine : Designed for the use of practitioners and students of medicine. New York: D. Appleton and Company, **1892**.
4. American Hospital Association. Hospitals and health systems face unprecedented financial pressures due to COVID-19. Available at: <https://www.aha.org/guidesreports/2020-05-05-hospitals-and-health-systems-face-unprecedented-financial-pressures-due>. Accessed 5 May 2020.
5. United Nations. This is how much the coronavirus will cost the world's economy, according to the UN. Available at: <https://www.weforum.org/agenda/2020/03/coronavirus-covid-19-cost-economy-2020-un-trade-economics-pandemic>. Accessed 3 May 2020.
6. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. *N Engl J Med* **2020**; 383(25):2451-60. doi: 10.1056/NEJMcp2009575. PMID: 32412710.
7. National Heart, Lung, and Blood Institute. Available at: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>. Accessed 27 May 2020.
8. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* **2020**; 382(18):1708-20. doi: 10.1056/NEJMoa2002032. PMID: 32109013.
9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA* **2020**; 323(20):2052-9. doi: 10.1001/jama.2020.6775. PMID: 32320003.
10. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1,591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* **2020**; 323(16):1574-81. doi: 10.1001/jama.2020.5394. PMID: 32250385.
11. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA* **2020**; 323(16):1612-4. doi: 10.1001/jama.2020.4326. PMID: 32191259.
12. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID-19 in critically ill patients in the Seattle region - case series. *N Engl J Med* **2020**; 382(21):2012-22. doi: 10.1056/NEJMoa2004500. PMID: 32227758.
13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **2020**; 395(10223):497-506. doi: 10.1016/s0140-6736(20)30183-5. PMID: 31986264.

14. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City. *N Engl J Med* **2020**; 382(24):2372-4. doi: [10.1056/NEJMc2010419](https://doi.org/10.1056/NEJMc2010419). PMID: [32302078](https://pubmed.ncbi.nlm.nih.gov/32302078/).
15. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. *Circ Res* **2020**; 126(10):1456-74. doi: [10.1161/circresaha.120.317015](https://doi.org/10.1161/circresaha.120.317015). PMID: [32264791](https://pubmed.ncbi.nlm.nih.gov/32264791/).
16. Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. *Crit Care* **2020**; 24(1):221. doi: [10.1186/s13054-020-02942-2](https://doi.org/10.1186/s13054-020-02942-2). PMID: [32410690](https://pubmed.ncbi.nlm.nih.gov/32410690/).
17. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* **2002**; 417(6891):822-8. doi: [10.1038/nature00786](https://doi.org/10.1038/nature00786). PMID: [12075344](https://pubmed.ncbi.nlm.nih.gov/12075344/).
18. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. *Nature* **2020**; 583(7816):437-40. doi: [10.1038/s41586-020-2355-0](https://doi.org/10.1038/s41586-020-2355-0). PMID: [32434211](https://pubmed.ncbi.nlm.nih.gov/32434211/).